Zydus Lifesciences Q2 FY27 consolidated revenue Rs 7,909.6 cr; PAT Rs 925.5 cr
For Q2 FY27, Zydus Lifesciences’ consolidated revenue from operations was Rs 7,909.60 cr and net profit Rs 925.50 cr, versus Rs 6,123.20 cr and Rs 1,260.90 cr a year earlier.
Key takeaways
- Revenue from operations Rs 7,909.60 cr vs Rs 6,123.20 cr a year earlier.
- Total income Rs 8,039.50 cr vs Rs 6,232.20 cr in the corresponding quarter.
- Profit before tax Rs 1,261.70 cr vs Rs 1,694.20 cr in Q2 last year.
- Net profit for the period Rs 925.50 cr vs Rs 1,260.90 cr a year earlier.
- Basic and diluted EPS Rs 9.28 vs Rs 12.53 in the corresponding prior quarter.
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 7,909.60 cr | Rs 6,123.20 cr | +29.2% |
| PAT | Rs 925.50 cr | Rs 1,260.90 cr | -26.6% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 11.70% of revenue, down 889 bps from 20.59%.
- Total expenses rose 51.0% while revenue rose 29.2%.
- Other expenses took 33.4% of revenue, against 29.3% a year earlier.
• Basis & period: Consolidated statement of unaudited financial results for the quarter ended 30/09/2026 (Q2 FY27), compared with the quarter ended 30/09/2025 in the same table.
• Revenue from operations (Total): Rs 7,909.60 cr for the quarter ended 30/09/2026 vs Rs 6,123.20 cr for the quarter ended 30/09/2025 (statement of consolidated unaudited financial results, line “Total revenue from operations”).
• Total income: Rs 8,039.50 cr vs Rs 6,232.20 cr (line “Total income”).
• Total expenses: Rs 6,806.60 cr vs Rs 4,509.00 cr (line “Total expenses”).
• Profit before share of profit of joint ventures, exceptional items and tax: Rs 1,232.90 cr vs Rs 1,723.20 cr (line “Profit before share of profit of joint ventures, exceptional items and tax (1-2)”).
• Share of profit of joint ventures (net of tax): Rs 27.50 cr vs Rs 5.20 cr (line “Share of profit of joint ventures (net of tax)”).
• Profit before exceptional items and tax: Rs 1,260.40 cr vs Rs 1,728.40 cr (line “Profit before exceptional items and tax (3+4)”).
• Exceptional items: Rs (1.30) cr vs Rs 34.20 cr (line “Exceptional items (Refer Note-4)”).
• Profit before tax: Rs 1,261.70 cr vs Rs 1,694.20 cr (line “Profit before tax (5-6)”).
• Total tax expenses: Rs 334.00 cr vs Rs 453.30 cr (line “Total tax expenses”).
• Net profit before non-controlling interests: Rs 927.70 cr vs Rs 1,240.90 cr (line “Net profit before non-controlling interests (7-8)”).
• Non-controlling interests: Rs 2.20 cr vs Rs (20.00) cr (line “Non-controlling interests”).
• Net profit for the period (PAT): Rs 925.50 cr vs Rs 1,260.90 cr (line “Net profit for the period/ year (9-10)”).
• Total Other Comprehensive Income: Rs (2.00) cr vs Rs (274.40) cr (line “Total Other Comprehensive Income”).
• Total Comprehensive Income (before attribution): Rs 928.70 cr vs Rs 966.50 cr (line “Total Comprehensive Income (9+12 d)”).
• Paid-up equity share capital: Rs 99.80 cr vs Rs 100.60 cr (line “Paid-up equity share capital (Face value Re. 1/-) (Refer Note-16)”).
• Earnings per share – Basic: Rs 9.28 vs Rs 12.53 (line “Basic (INR)”).
• Earnings per share – Diluted: Rs 9.28 vs Rs 12.53 (line “Diluted (INR)”).
In Q2 FY27, consolidated revenue from operations (sale of products plus other operating revenues) for Zydus Lifesciences Limited increased to Rs 7,909.60 cr from Rs 6,123.20 cr in the corresponding quarter of the previous year, according to the statement of consolidated unaudited financial results. Total income, which includes other income, rose to Rs 8,039.50 cr from Rs 6,232.20 cr.
Total expenses moved up to Rs 6,806.60 cr from Rs 4,509.00 cr, with higher reported lines including cost of materials consumed, purchases of stock-in-trade, employee benefits expense, depreciation and amortisation expense, and other expenses. The line item “Net (gain) on foreign currency transactions” is shown as Rs (136.60) cr for the current quarter versus Rs (414.10) cr a year earlier within total expenses.
Profit before share of profit of joint ventures, exceptional items and tax stood at Rs 1,232.90 cr compared with Rs 1,723.20 cr in the year-ago quarter. After including the share of profit of joint ventures (net of tax) of Rs 27.50 cr (vs Rs 5.20 cr), profit before exceptional items and tax was Rs 1,260.40 cr versus Rs 1,728.40 cr.
Exceptional items for the quarter are reported at Rs (1.30) cr, compared with Rs 34.20 cr in Q2 of the previous year. Profit before tax is shown at Rs 1,261.70 cr against Rs 1,694.20 cr. Total tax expenses were Rs 334.00 cr versus Rs 453.30 cr.
Net profit before non-controlling interests came in at Rs 927.70 cr versus Rs 1,240.90 cr, and after accounting for non-controlling interests of Rs 2.20 cr (vs Rs (20.00) cr), net profit for the period attributable to owners is Rs 925.50 cr compared with Rs 1,260.90 cr a year earlier. Basic and diluted earnings per share for the quarter are both reported at Rs 9.28, down from Rs 12.53 in the corresponding prior period.
Get Zydus Lifesciences Ltd's next results the minute they're filed
Results reach the exchange at all hours, most of them after the market closes. Pro puts the filing in your feed as it is published, with our read of the numbers. A free account sees it an hourback for a day.
- We'll start you off following ZYDUSLIFE.
- 14 days free, no card. After that you keep a free account.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.